Cashin Richard M Jr's Form 4/A amendment
AmendedAdaptHealth Corp. (AHCO) · filed Mar 30, 2026
- Accession no.
- 0001193125-26-132703
- Filed
- Mar 30, 2026, 7:49 PM ET
- Trade date
- Mar 19-20, 2026
- Filing delay
- 11 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 23, 2026
This filing lists 2 non-derivative transactions. It carries over 3 transactions from the original filing that it did not restate. Open-market purchases total $24.4M. It was filed 11 days after the trade.
This amendment restates part of 0001193125-26-132663 (filed Mar 30, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cashin Richard M JrCIK 0001172898 | 10% Owner |
| One Equity Partners VII, L.P.CIK 0001733523 | 10% Owner |
| One Equity Partners VII-A, L.P.CIK 0001733525 | 10% Owner |
| One Equity Partners VII-B, L.P.CIK 0001733528 | 10% Owner |
| OEP AHCO Investment Holdings, LLCCIK 0001817112 | 10% Owner |
| OEP VII General Partner, L.P.CIK 0001817115 | 10% Owner |
| Oep VII GP, L.L.C.CIK 0001817118 | 10% Owner |
| OEP VII Project A Co-Investment Partners, L.P.CIK 0001817120 | 10% Owner |
| Oep VII Project A-I Co-Investment Partners, L.P.CIK 0001821208 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001193125-26-132663 (filed Mar 30, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Common Stock | PPurchaseAcquired | +820,528 | $9.73F1 | +$7,982,670.75 | 14,638,708 | Indirect | |
| Mar 11, 2026 | Common Stock | PPurchaseAcquired | +536,827 | $9.73F4 | +$5,222,306.74 | 15,175,535 | Indirect | |
| Mar 12, 2026 | Common Stock | PPurchaseAcquired | +689,336 | $9.73F5 | +$6,707,170.35 | 15,864,871 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.58 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.64 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.55 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").
- F3
(Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.
- F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
This filing is being amended solely to reflect Investor, the Parallel Funds, OEP VII GP, OEP VII GP LLC (collectively, the "OEP Entities") as reporting persons and direct and indirect holders of the reported securities, which were previously reported on a Form 4 that was timely filed by Richard Cashin on March 23, 2026 (the "Original Form 4 Filing"). As noted in the remarks, the Original Form 4 Filing disclosed the OEP Entities' direct and indirect ownership and noted that Edgar filing codes were not available at such time but that the Original Form 4 Filing would be amended once such codes became available.